Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 4/2017

Open Access 01-12-2017 | Systemic Therapies (M Liu and T Haddad, Section Editors)

Pre-operative Endocrine Therapy

Authors: Laura M. Arthur, Arran K. Turnbull, Lucy R. Khan, J. Michael Dixon

Published in: Current Breast Cancer Reports | Issue 4/2017

Login to get access

Abstract

Purpose of Review

Pre-operative endocrine therapy can be used to down-stage large or locally advanced breast cancers in ER+ disease. In the last four decades, it has evolved from a treatment perceived as an alternative to surgery for those too unfit to undergo surgery or chemotherapy, to the present day where it is a valuable and valid option in the treatment of postmenopausal women with ER-rich (Allred score 7–8, or > 50% staining for ER) breast cancer.

Recent Findings

Emerging data from the metastatic setting is translating into neoadjuvant trials, utilising dual endocrine targeting or combinations of endocrine agents and other targeted drugs, including those acting against components of the PI3K pathway and the cell cycle. The routine use of peri-operative endocrine therapy in all ER+ tumours may help to yield important long-term prognostic information, and guide adjuvant endocrine therapy.

Summary

Pre-operative endocrine therapy is an exciting and evolving area with emerging new approaches. In this review, established evidence and emerging data on its applications are discussed.
Literature
1.
Perloff M, Lesnick GJ. Chemotherapy before and after mastectomy in stage III breast cancer. Arch Surg. 1982;117(7):879–81.CrossRefPubMed
2.
Fisher B, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483–93.CrossRefPubMed
3.
Dixon JM. Role of endocrine therapy in the neoadjuvant surgical setting. Ann Surg Oncol. 2004;11(1 Suppl):18S–23S.CrossRefPubMed
4.
Macaskill EJ, Dixon JM. Neoadjuvant use of endocrine therapy in breast cancer. Breast J. 2007;13(3):243–50.CrossRefPubMed
5.
von Minckwitz G, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30(15):1796–804.CrossRef
6.
Cance WG, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg. 2002;236(3):295–302. discussion 302–3CrossRefPubMedPubMedCentral
7.
Makris A, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998;9(11):1179–84.CrossRefPubMed
8.
Semiglazov VF, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110(2):244–54.CrossRefPubMed
9.
Spring LM, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477–86.CrossRefPubMed
10.
Cortazar P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.CrossRefPubMed
11.
Carey LA, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–34.CrossRefPubMed
12.
Colleoni M, et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat. 2009;116(2):359–69.CrossRefPubMed
13.
Aebi S, et al. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol. 2011;22(9):1981–7.CrossRefPubMedPubMedCentral
14.
Coates AS, Colleoni M, Goldhirsch A. Is adjuvant chemotherapy useful for women with luminal a breast cancer? J Clin Oncol. 2012;30(12):1260–3.CrossRefPubMed
15.
Preece PE, et al. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed). 1982;284(6319):869–70.CrossRef
16.
Hind D, et al. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2006;1:CD004272.
17.
Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer. 2002;38(17):2214–21.CrossRefPubMed
18.
Ellis MJ, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19(18):3808–16.CrossRefPubMed
19.
Carlson GW. Total mastectomy under local anesthesia: the tumescent technique. Breast J. 2005;11(2):100–2.CrossRefPubMed
20.
Dixon JM, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat. 2001;66(3):191–9.CrossRefPubMed
21.
Dowsett M, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–18.CrossRefPubMed
22.
Regan MM, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011;12(12):1101–8.CrossRefPubMedPubMedCentral
23.
Eiermann W, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527–32.CrossRefPubMed
24.
Ellis MJ, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003;63(19):6523–31.PubMed
25.
Smith IE, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–16.CrossRefPubMed
26.
Cataliotti L, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–103.CrossRefPubMed
27.
Semiglazov V, et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER plus breast cancer (T2N 1-2, T3NO-1, T4NOMO). J Clin Oncol. 2005;23(16):11s.
28.
Seo JH, Kim YH, Kim JS. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer. Cancer Chemother Pharmacol. 2009;63(2):261–6.CrossRefPubMed
29.
Cohen AL, et al. POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase ompliance) trial: changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen. Breast. 2017;31:219–23.CrossRefPubMed
30.
Masuda N, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012;13(4):345–52.CrossRefPubMed
31.
Alba E, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23(12):3069–74.CrossRefPubMed
32.
Ellis MJ, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9.CrossRefPubMedPubMedCentral
33.
Murray J, et al. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women. Breast Cancer Res Treat. 2009;114(3):495–501.CrossRefPubMed
34.
Dixon JM, et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat. 2009;113(1):145–51.CrossRefPubMed
35.
Toi M, et al. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Sci. 2011;102(4):858–65.CrossRefPubMed
36.
Carpenter R, et al. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. Breast Cancer Res Treat. 2014;144(3):569–76.CrossRefPubMed
37.
Guarneri V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24(7):1037–44.CrossRefPubMed
38.
Palmieri C, et al. NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. Breast Cancer Res Treat. 2014;148(3):581–90.CrossRefPubMed
39.
Sheri A, Dowsett M. Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. Ann Oncol. 2012;23(Suppl 10):x219–27.CrossRefPubMed
40.
Jones RL, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009;116(1):53–68.CrossRefPubMed
41.
Dowsett M, et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res. 2006;12(3 Pt 2):1024s–30s.CrossRefPubMed
42.
Akashi-Tanaka S, et al. 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. Breast. 2009;18(3):171–4.CrossRefPubMed
43.
Ueno T, et al. Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. Int J Clin Oncol. 2014;19(4):607–13.CrossRefPubMed
44.
Ellis MJ, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100(19):1380–8.CrossRefPubMedPubMedCentral
45.
Turnbull AK, et al. Accurate prediction and validation of response to endocrine therapy in breast cancer. J Clin Oncol. 2015;33(20):2270–8.CrossRefPubMed
46.
Ellis MJ, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol, 2017: p. JCO2016694406.
47.
Dowsett M, et al. Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J Natl Cancer Inst Monogr. 2011;2011(43):120–3.CrossRefPubMed
48.
Finn RS, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.CrossRefPubMed
49.
Finn RS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.CrossRefPubMed
50.
Ma CX, et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res, 2017.
51.
Hurvitz S, Martin M, Fernández Abad M, Chan D, Rostorfer R, Petru E, Barriga S, Costigan TM, Caldwell CW, Nguyen T, Press M, Slamon D, Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2- breast cancer. San Antonio Breast Cancer Symposium, 2016. 2016 (Abstract S4–06).
52.
Baselga J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(16):2630–7.CrossRef
53.
Suman VJ, Ellis MJ, Ma CX. The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2− invasive breast cancer. Chin Clin Oncol. 2015;4(3):34.PubMedPubMedCentral
Metadata
Title
Pre-operative Endocrine Therapy
Authors
Laura M. Arthur
Arran K. Turnbull
Lucy R. Khan
J. Michael Dixon
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 4/2017
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-017-0255-6

Other articles of this Issue 4/2017

Current Breast Cancer Reports 4/2017 Go to the issue

Systemic Therapies (M Liu and T Haddad, Section Editors)

Immunotherapy Approaches to Breast Cancer

Systemic Therapies (M Liu and T Haddad, Section Editors)

Androgen Receptor-Targeted Therapy for Breast Cancer

Breast Cancer Screening and Imaging (HTC Le-Petross and BE Adrada, Section Editors)

How Effective Is Mammography as a Screening Tool?

Breast Cancer Screening and Imaging (HTC Le-Petross and BE Adrada, Section Editors)

Axillary Nodal Staging with Contrast-Enhanced Ultrasound

Systemic Therapies (M Liu and T Haddad, Section Editors)

Treatment of Breast Cancer During Pregnancy

Systemic Therapies (M Liu and T Haddad, Section Editors)

The Double-Edged Sword: Controversies in Anthracycline-Based Chemotherapy for Breast Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits